No description available.

Orientador: Gisele Fabrino Machado / Banca: Felipe Augusto Ruiz Sueiro / Banca: Antonio Carlos Alessi / Resumo: A causa dos tumores da glândula perianal é desconhecida, entretanto eles podem ser modulados por influência de hormônios gonadais, basicamente a testosterona, uma vez que há uma alta prevalência (até 95%) de regressão da forma benigna dessa neoplasia após a castração dos machos. A proteína Ki-67 foi descrita pela primeira vez em 1983 é uma proteína nãohistona, que não é expressa em células na fase G0, mas que pode ser detectada nas fases ativas do ciclo celular, G1, S, G2 e mitose Verificou-se que o Ki-67 está associado com a proliferação celular, estando a população de células tumorais positivas ao Ki-67 correlacionada com a evolução clínica da doença. Foram estudados 42 casos de neoplasias da glândula perineal, sendo 15 adenomas, 15 epiteliomas, 12 carcinomas. Foram utilizadas 13 amostras de tecido de glândula perianal normal, como controle. De cada animal foram obtidas informações como: sexo, idade, raça, presença de outras neoplasias, se castrado ou não, se em caso de fêmea havia o uso de anticoncepcional, tempo de evolução, recidiva e tempo de sobrevida. Dos 42 casos de neoplasias de glândulas perianais, 34 (80,95%) foram provenientes de cães machos e 8 (19,05%) de fêmeas. A média de idade dos machos com a neoplasia foi de 9,8 anos, e das fêmeas 7,4 anos, sendo que para os dois sexos a idade variou de 5 a 15 anos. Em relação às raças, 11 (26,19%) eram S.R.D. (sem raça definida), 9 (21,42%) Poodle, 4 (9,52%) Cocker Spaniel e Husky Siberiano. O histórico de diagnóstico de outras neoplasias, foi constatado em 23,80% dos animais deste estudo. Em relação à castração, 32 (94,11%) dos machos não eram castrados e apenas 8 (19,05%) fêmeas eram. O tempo de evolução da neoplasia apresentou média de 1,2 anos. Histórico de recidiva da neoplasia foram relatados em 14 animais, sendo maior... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: The cause of perianal gland tumors is unknown, though they may be modulated by the influence of gonadal hormones, primarily testosterone, since there is a high prevalence (up to 95%) of regression of the benign tumor after males castration. Protein Ki-67 was first described in 1983, and it is a nonhistone protein, which is not expressed in G0 phase cells, but can be detected in the active phases of the cell cycle, G1, S, G2 and mitosis. It was found that Ki-67 is associated with cell proliferation, and the population of tumor cells positive for Ki-67 correlated with clinical outcome. In this present work we studied 42 cases of perineal gland neoplasms, being 15 adenomas, 15 epitheliomas and 12 carcinomas. We used 13 tissue samples of normal perianal gland as control. From each animal we obtained information such as gender, age, race, presence of other malignancies, neutering status, whether if there were female contraceptive use, duration, recurrence and survival time. Of the 42 cases of perianal gland neoplasms, 34 (80.95%) were from males and eight dogs (19.05%) females. The males average age with cancer was 9.8 years and 7.4 years for females and for both sexes aged between 5 and 15 years. In regard to race, 11 (26.19%) were no breed, 9 (21.42%) were Poodle, and 4 (9.52%) were Siberian Husky and Cocker Spaniels. The history of diagnosis of other cancers, was found in 23.80% of the animals in this study. In relation to castration, 32 (94.11%) of males were not castrated and only 8 (19.05%) were females. The progression of the tumor showed an average of 1.2 years. History of recurrence of cancer were reported in 14 animals, and was higher (66.66%) for carcinomas. Ki-67 staining revealed that the carcinomas showed higher proliferation rate (9.87%) compared to groups of epitheliomas... (Complete abstract click electronic access below) / Mestre

Made available in DSpace on 2014-06-11T19:27:18Z (GMT). No. of bitstreams: 0 Previous issue date: 2011-03-18Bitstream added on 2014-06-13T19:35:13Z : No. of bitstreams: 1 pereira_rs_me_araca.pdf: 790587 bytes, checksum: 194f37c505d12a98d7b75720d14a4e5f (MD5) / A causa dos tumores da glândula perianal é desconhecida, entretanto eles podem ser modulados por influência de hormônios gonadais, basicamente a testosterona, uma vez que há uma alta prevalência (até 95%) de regressão da forma benigna dessa neoplasia após a castração dos machos. A proteína Ki-67 foi descrita pela primeira vez em 1983 é uma proteína nãohistona, que não é expressa em células na fase G0, mas que pode ser detectada nas fases ativas do ciclo celular, G1, S, G2 e mitose Verificou-se que o Ki-67 está associado com a proliferação celular, estando a população de células tumorais positivas ao Ki-67 correlacionada com a evolução clínica da doença. Foram estudados 42 casos de neoplasias da glândula perineal, sendo 15 adenomas, 15 epiteliomas, 12 carcinomas. Foram utilizadas 13 amostras de tecido de glândula perianal normal, como controle. De cada animal foram obtidas informações como: sexo, idade, raça, presença de outras neoplasias, se castrado ou não, se em caso de fêmea havia o uso de anticoncepcional, tempo de evolução, recidiva e tempo de sobrevida. Dos 42 casos de neoplasias de glândulas perianais, 34 (80,95%) foram provenientes de cães machos e 8 (19,05%) de fêmeas. A média de idade dos machos com a neoplasia foi de 9,8 anos, e das fêmeas 7,4 anos, sendo que para os dois sexos a idade variou de 5 a 15 anos. Em relação às raças, 11 (26,19%) eram S.R.D. (sem raça definida), 9 (21,42%) Poodle, 4 (9,52%) Cocker Spaniel e Husky Siberiano. O histórico de diagnóstico de outras neoplasias, foi constatado em 23,80% dos animais deste estudo. Em relação à castração, 32 (94,11%) dos machos não eram castrados e apenas 8 (19,05%) fêmeas eram. O tempo de evolução da neoplasia apresentou média de 1,2 anos. Histórico de recidiva da neoplasia foram relatados em 14 animais, sendo maior... / The cause of perianal gland tumors is unknown, though they may be modulated by the influence of gonadal hormones, primarily testosterone, since there is a high prevalence (up to 95%) of regression of the benign tumor after males castration. Protein Ki-67 was first described in 1983, and it is a nonhistone protein, which is not expressed in G0 phase cells, but can be detected in the active phases of the cell cycle, G1, S, G2 and mitosis. It was found that Ki-67 is associated with cell proliferation, and the population of tumor cells positive for Ki-67 correlated with clinical outcome. In this present work we studied 42 cases of perineal gland neoplasms, being 15 adenomas, 15 epitheliomas and 12 carcinomas. We used 13 tissue samples of normal perianal gland as control. From each animal we obtained information such as gender, age, race, presence of other malignancies, neutering status, whether if there were female contraceptive use, duration, recurrence and survival time. Of the 42 cases of perianal gland neoplasms, 34 (80.95%) were from males and eight dogs (19.05%) females. The males average age with cancer was 9.8 years and 7.4 years for females and for both sexes aged between 5 and 15 years. In regard to race, 11 (26.19%) were no breed, 9 (21.42%) were Poodle, and 4 (9.52%) were Siberian Husky and Cocker Spaniels. The history of diagnosis of other cancers, was found in 23.80% of the animals in this study. In relation to castration, 32 (94.11%) of males were not castrated and only 8 (19.05%) were females. The progression of the tumor showed an average of 1.2 years. History of recurrence of cancer were reported in 14 animals, and was higher (66.66%) for carcinomas. Ki-67 staining revealed that the carcinomas showed higher proliferation rate (9.87%) compared to groups of epitheliomas... (Complete abstract click electronic access below)

No description available.

Em mulheres, o câncer de mama é o tipo mais incidente depois do tumor de pele não melanoma e é a principal causa de morte por câncer. Apesar dos avanços já alcançados na caracterização da doença, a busca por novos marcadores moleculares para diagnóstico, tratamento e entendimento molecular da doença é de extrema importância. Estudos em nosso laboratório apontaram a proteína EMC1 (do inglês, Endoplasmic Reticulum Complex 1) como relacionada a propriedades malignas em linhagens celulares de câncer de mama e melanoma, assim como aumento no crescimento tumoral em ensaios in vivo. Despertou-se, então, o interesse em nosso laboratório, no estudo das outras proteínas do complexo EMC. Este estudo atual, busca analisar dados em larga escala do banco TCGA em um painel de 32 tipos tumorais, e aponta associação da expressão de diversas proteínas EMCs a pior sobrevida dos pacientes. O gene EMC2, que se localiza na região cromossômica altamente amplificada em diversos tumores (8q23.1), se destaca pela intensidade de pacientes com superexpressão em câncer de mama (40%). Em linhagens desse tipo tumoral, o knockdown de EMC2 aponta redução na taxa proliferativa, assim como associação à progressão do ciclo celular na fase M, quando feito o protocolo de sincronização utilizando a droga nocodazol. Em conjunto, nossos dados sugerem que o complexo EMC pode favorecer o desenvolvimento de tumores e influenciar em sua malignidade. Além disso, a proteína EMC2 parece apresentar funções relacionadas a proliferação e possivelmente, ciclo celular. / In woman, the breast cancer is the most incidence type after skin tumor non melanoma and it is a main cause of cancer death. Despite the advances already achieved in the disease caracterization, the search for novel molecular biomarkers to diagnostic, treatment and disease knowledge is extremely importante. In vitro approaches pointed Endoplasmic Reticulum Complex 1 (EMC1) involvement in malignant properties in breast cancer and melanoma cell lines, and increase in tumor growth in a in vivo assay. It highlighted the study of the other members of EMC complex. In this study, we used a large-scale database from TCGA in a range of 32 tumoral types, and showed association in EMC expression and poor surviving curve. The EMC2 gene, localized in a high amplified chromosome region in cancer (8q23.1), have a interesting upregulation level in breast cancer (40%). In knockdown EMC2 cell lines, the proliferation is less intense and progression in M phase, in a nocodazole sincronization assay, is impaired. Together, the data suggest that the EMC complex favors the tumour development and the EMC2 protein seens to play a role in proliferation and maybe in cell cycle.

Em mulheres, o câncer de mama é o tipo mais incidente depois do tumor de pele não melanoma e é a principal causa de morte por câncer. Apesar dos avanços já alcançados na caracterização da doença, a busca por novos marcadores moleculares para diagnóstico, tratamento e entendimento molecular da doença é de extrema importância. Estudos em nosso laboratório apontaram a proteína EMC1 (do inglês, Endoplasmic Reticulum Complex 1) como relacionada a propriedades malignas em linhagens celulares de câncer de mama e melanoma, assim como aumento no crescimento tumoral em ensaios in vivo. Despertou-se, então, o interesse em nosso laboratório, no estudo das outras proteínas do complexo EMC. Este estudo atual, busca analisar dados em larga escala do banco TCGA em um painel de 32 tipos tumorais, e aponta associação da expressão de diversas proteínas EMCs a pior sobrevida dos pacientes. O gene EMC2, que se localiza na região cromossômica altamente amplificada em diversos tumores (8q23.1), se destaca pela intensidade de pacientes com superexpressão em câncer de mama (40%). Em linhagens desse tipo tumoral, o knockdown de EMC2 aponta redução na taxa proliferativa, assim como associação à progressão do ciclo celular na fase M, quando feito o protocolo de sincronização utilizando a droga nocodazol. Em conjunto, nossos dados sugerem que o complexo EMC pode favorecer o desenvolvimento de tumores e influenciar em sua malignidade. Além disso, a proteína EMC2 parece apresentar funções relacionadas a proliferação e possivelmente, ciclo celular. / In woman, the breast cancer is the most incidence type after skin tumor non melanoma and it is a main cause of cancer death. Despite the advances already achieved in the disease caracterization, the search for novel molecular biomarkers to diagnostic, treatment and disease knowledge is extremely importante. In vitro approaches pointed Endoplasmic Reticulum Complex 1 (EMC1) involvement in malignant properties in breast cancer and melanoma cell lines, and increase in tumor growth in a in vivo assay. It highlighted the study of the other members of EMC complex. In this study, we used a large-scale database from TCGA in a range of 32 tumoral types, and showed association in EMC expression and poor surviving curve. The EMC2 gene, localized in a high amplified chromosome region in cancer (8q23.1), have a interesting upregulation level in breast cancer (40%). In knockdown EMC2 cell lines, the proliferation is less intense and progression in M phase, in a nocodazole sincronization assay, is impaired. Together, the data suggest that the EMC complex favors the tumour development and the EMC2 protein seens to play a role in proliferation and maybe in cell cycle.

Micro (mi)RNAs have recently been found to play an important role in cancer biology. In order to further understand how miRNAs affect prostate tumour progression, we evaluated miRNA expression in two invasive prostate tumour lines, PC3 and DU145. We then focused our evaluation on a novel miRNA, miR-105, whose levels were significantly decreased in both tumour cell lines as compared to normal prostate epithelial cells. As miR-105 levels were reduced in prostate tumour cell lines, we restored its expression following transfection of cells with mimic constructs to over-express miR-105 in both cell lines, in order to determine its effect on various tumourigenic properties. Over-expression caused decreased tumour cell proliferation, anchorage-independent growth and invasion in vitro and inhibited tumour growth in vivo. We further identified CDK6 as a putative target of miR-105, which likely contributed to its inhibition of tumour cell growth. Our results suggest that miR-105 inhibits tumour cell proliferation and may be an interesting target to regulate tumour growth or potentially used as a biomarker to differentiate between less and more aggressive tumours in patients.

Micro (mi)RNAs have recently been found to play an important role in cancer biology. In order to further understand how miRNAs affect prostate tumour progression, we evaluated miRNA expression in two invasive prostate tumour lines, PC3 and DU145. We then focused our evaluation on a novel miRNA, miR-105, whose levels were significantly decreased in both tumour cell lines as compared to normal prostate epithelial cells. As miR-105 levels were reduced in prostate tumour cell lines, we restored its expression following transfection of cells with mimic constructs to over-express miR-105 in both cell lines, in order to determine its effect on various tumourigenic properties. Over-expression caused decreased tumour cell proliferation, anchorage-independent growth and invasion in vitro and inhibited tumour growth in vivo. We further identified CDK6 as a putative target of miR-105, which likely contributed to its inhibition of tumour cell growth. Our results suggest that miR-105 inhibits tumour cell proliferation and may be an interesting target to regulate tumour growth or potentially used as a biomarker to differentiate between less and more aggressive tumours in patients.

No description available.

Micro (mi)RNAs have recently been found to play an important role in cancer biology. In order to further understand how miRNAs affect prostate tumour progression, we evaluated miRNA expression in two invasive prostate tumour lines, PC3 and DU145. We then focused our evaluation on a novel miRNA, miR-105, whose levels were significantly decreased in both tumour cell lines as compared to normal prostate epithelial cells. As miR-105 levels were reduced in prostate tumour cell lines, we restored its expression following transfection of cells with mimic constructs to over-express miR-105 in both cell lines, in order to determine its effect on various tumourigenic properties. Over-expression caused decreased tumour cell proliferation, anchorage-independent growth and invasion in vitro and inhibited tumour growth in vivo. We further identified CDK6 as a putative target of miR-105, which likely contributed to its inhibition of tumour cell growth. Our results suggest that miR-105 inhibits tumour cell proliferation and may be an interesting target to regulate tumour growth or potentially used as a biomarker to differentiate between less and more aggressive tumours in patients.